Abstract Library

#2795 Molecular Correlation of the Activity of Evofosfamide (EVO) in Combination with Sunitinib (SUN) in Pancreatic Neuroendocrine Tumors (pNETs) in the SUNEVO GETNE Trial

Introduction: MEN1, DAXX, ATRX, and PI3K/AKT/mTOR pathway genes are frequently mutated in pNETs. Sunitinib is approved and widely used in the metastatic setting but unfortunately, no validated predictive biomarker has been identified to guide therapy yet. The SUNEVO phase II trial of the Spanish Task Force Group for Neuroendocrine and Endocrine Tumours (GETNE) trial combined the pro-drug of EVO under SUN-induced hypoxic conditions.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Santos M, Lanillos J, Lopez C, Alonso Gordoa T, Benavent M,

Keywords: pancreatic, neuroendocrine, mutations, correlation,

#2283 Ultra-Deep Targeted Resequencing Reveals Recurrent DAXX and CYFIP2 Mutations and Implicates Novel Pathways in Pancreatic Neuroendocrine Tumors

Introduction: Recent studies in pancreatic neuroendocrine tumors have identified mutations in DAXX/ATRX, MEN1, and genes involved in the phosphoinositide-3-kinase/Akt/mammalian target of rapamycin (PI3K-Akt-mTOR) pathway. However, these studies focused on abundant mutations.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Vandamme T

Authors: Vandamme T, Beyens M, Van Camp G, Boons G, Hofland L,

Keywords: pancreatic neuroendocrine tumors, PNET, genetics, tumor heterogeneity, hotspot mutations,

#2205 Analysis of MET and RET Expression in Patients with Pancreatic Neuroendocrine Tumors Receiving Everolimus

Introduction: Target therapy has improved the outcome of neuroendocrine tumors (NETs), but little is known about the strategies to overcome the acquired resistance. MET is considered one of the putative mechanisms of resistance. RET is also rearranged in some other endocrine tumors (like thyroid).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Cella C, Barberis M, Spad F, Pisa E, Laffi A,

Keywords: Everolimus, MET, RET,

#1840 Genetic Features and Immunoprofile of Sporadic Well-Differentiated Neuroendocrine Tumors of Gastric

Introduction: Well-differentiated Type III gastric neuroendocrine tumors (gNET III) are histologically distinct subset that have a unique pathogenesis and clinical course.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Ji Y

Authors: Xie Y, Xu Y, Zeng H, Wang H, Hou Y,

Keywords: genetic, wdnet.,

#1775 Potential Therapeutic Targets for Gastric Poorly Differentiated Neuroendocrine Carcinoma

Introduction: Gastric poorly differentiated neuroendocrine carcinoma (G-PDNEC) is rare and aggressive. Patients often present with distant metastases at initial diagnosis.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: JI Y

Authors: Ji Y, Xie Y, Chen K, Zeng H, Sun Y,

Keywords: gastric, neuroendocrine carcinoma, mTOR pathway, SSTR, targeted therapies,